Human focal cerebral infarctions induce differential lesional interleukin-16 (IL-16) expression confined to infiltrating granulocytes, CD8+ T-lymphocytes and activated microglia/macrophages

Journal of Neuroimmunology

Volumn 114, Issue 1-2, 2001, Pages 232-241

  Schwab, J M ^a   Nguyen, T D ^a   Meyermann, R ^a   Schluesener, H J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Blood brain barrier; Cell recruitment; Inflammation; Microthrombosis; Secondary damage

Indexed keywords

CD8 ANTIGEN; INTERLEUKIN 16;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN INFARCTION; BRAIN INJURY; BRAIN ISCHEMIA; CELL DEATH; ENDOTHELIUM CELL; HUMAN; HUMAN TISSUE; IMMEDIATE EARLY GENE; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATION; MACROPHAGE ACTIVATION; MICROTHROMBUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BLOOD-BRAIN BARRIER; BRAIN ISCHEMIA; CD8-POSITIVE T-LYMPHOCYTES; CEREBRAL INFARCTION; ENCEPHALITIS; FEMALE; GRANULOCYTES; HUMANS; INTERLEUKIN-16; LYMPH NODES; MACROPHAGES; MALE; MICROGLIA; MIDDLE AGED;

EID: 0035283489     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(00)00433-1     Document Type: Article

References (54)

1. Inflammatory mediators and modulation of blood-brain barrier permeability
2. Expression of interleukin-16 by human epithelial cells. Inhibition by dexamethasone
3. Dynamics of polymorphonuclear leukocyte accumulation in acute cerebral infarction and their correlation with brain tissue damage
4. Fighting HIV-1 with IL-16
5. Inflammatory mediators and stroke: New opportunities for novel therapeutics
6. Interleukin-16 or not?
7. Inflammation and acute stroke
8. Immunologic tolerance to myelin basic protein decreases stroke size after transient focal cerebral ischemia
9. The lymphocyte chemoattractant factor
10. Interleukin 16
11. Interleukin 16 and its function as a CD4 ligand
12. Modulation of lymphocyte migration by human lymphokines. I. Identification and characterization of chemoattractant activity for lymphocytes from mitogen-stimulated mononuclear cells
13. Tissue and T cell distribution of precursor and mature IL-16
14. Signaling and functional properties of interleukin-16
15. Early identification of interleukin-16 (lymphocyte chemoattractant factor) and macrophage inflammatory protein 1 alpha (MIP1 alpha) in bronchoalveolar lavage fluid of antigen-challenged asthmatics
16. Molecular and functional analysis of a lymphocyte chemoattractant factor: Association of biologic function with CD4 expression
17. Lymphocyte chemoattractant factor induces CD4-dependent intracytoplasmic signaling in lymphocytes
18. Lymphokine activation of T4+ T lymphocytes and monocytes
19. Macrophages can modify the nonpermissive nature of the adult mammalian central nervous system
20. Clinical trials with neuroprotective drugs in acute ischaemic stroke: Are we doing the right thing?
21. Inflammation and stroke: Putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia
22. Pathobiology of ischemic stroke: An integrated view
23. Cytokines in brain ischemia - The role of TNF alpha
24. Interleukin-16, produced by synovial fibroblasts, mediates chemoattraction for CD4+ T lymphocytes in rheumatoid arthritis
25. Tumor necrosis factor-alpha augments pulmonary arterial transendothelial albumin flux in vitro
26. Focal ischaemia of the rat brain elicits an unusual inflammatory response: Early appearance of CD8+ macrophages/microglia
27. Vascular diseases
28. The initiation of the microglial response
29. Interleukin 16 (IL-16) IUIS/WHO Standing Committee on Interleukin Designation
30. Conservation of structure and function between human and murine IL-16
31. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke
32. IL-16 activates the SAPK signaling pathway in CD4+ macrophages
33. Phenotype of IL-16-producing cells in bronchial mucosa: Evidence for the human eosinophil and mast cell as cellular sources of IL-16 in asthma
34. The changing landscapes of ischaemic brain injury
35. Ischemic cell death in brain neurons
36. Identification of a CD4 domain required for interleukin-16 binding and lymphocyte activation
37. IL-16 represses HIV-1 promoter activity
38. Cutting edge: CD4 is not required for the functional activity of IL-16
39. Structure of interleukin 16 resembles a PDZ domain with an occluded peptide binding site
40. PDZ domains: Targeting signalling molecules to sub-membranous sites
41. Expression of the S-100 proteins MRP-8 and -14 in ischemic brain lesions
42. Fibrin activation of vascular endothelial cells. Induction of IL-8 expression
43. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats
44. Neuroglial activation repertoire in the injured brain: Graded response, molecular mechanisms and cues to physiological function
45. The CD4-associated tyrosine kinase p56lck is required for lymphocyte chemoattractant factor-induced T lymphocyte migration
46. Leukocyte chemotactic factor, a natural ligand to CD4, is expressed by lymphocytes and microglial cells of the MS plaque
47. Selective accumulation of cyclooxygenase-1-expressing microglial cells/macrophages in lesions of human focal cerebral ischemia
48. Cultured human fibroblasts express constitutive IL-16 mRNA: Cytokine induction of active IL-16 protein synthesis through a caspase-3-dependent mechanism
49. Inflammation and glial responses in ischemic brain lesions
50. Reactive microgliosis
51. IL-16 anti-HIV-1 therapy
52. Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats
53. Processing and activation of pro-interleukin-16 by caspase-3
54. Human CD4+ cells transfected with IL-16 cDNA are resistant to HIV-1 infection: Inhibition of mRNA expression